1. Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia 
Andrew G. Bostom, MD, Alexandra MacLean, Darbie Maccubbin, Diane Tipping, Hilde Gizek, William Hanlon 
Journal of Clinical Lipidology 
Volume 4, Issue 3, Pages (May 2010)
DOI: /j.jacl
Copyright © 2010 National Lipid Association Terms and Conditions

2. Figure
Serum phosphorus concentrations by treatment group at baseline (week 0), and weeks 4, 8, 12, 18, 24, 30, and 36, among those with a baseline serum phosphorus of >3.5 mg/dL. ERN-L, extended-release niacin + laropiprant.
Journal of Clinical Lipidology 2010 4, DOI: ( /j.jacl )
Copyright © 2010 National Lipid Association Terms and Conditions